Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to local medical professionals. "I think it could be a potentially ...
The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and ...
Journavx is a newly-aproved painkiller that experts say could help Long Island's opioid epidemic. NewsdayTV's Virginia Huie reports.
Want a say in the news? Email Claudia at [email protected] to have your thoughts on the stories covered here or on ...
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback